First Wave BioPharma, Inc. has had to navigate some choppy waters in the past few months but the US firm has pulled off something of a coup by bagging the rights to an old Sanofi compound for peanuts.
First Wave Rises With Sanofi GI Deal
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.
More from Deals
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
The German group is paying $3.9bn to get hold of the US firm and its two approved products.